Purple Biotech (PPBT) Assets Average (2014 - 2026)

Purple Biotech (PPBT) has 13 years of Assets Average data on file, last reported at $16.0 million in Q1 2026.

• On a quarterly basis, Assets Average fell 55.96% year-over-year to $16.0 million in Q1 2026; TTM through Mar 2026 was $16.0 million, a 55.96% decrease from a year earlier, with the FY2025 full-year figure at $27.3 million, down 32.86% from the prior year.
• Assets Average for Q1 2026 stood at $16.0 million, down from $28.3 million in the prior quarter.
• Over the last five years, Assets Average for PPBT reached as high as $68.2 million in Q1 2022 and fell as low as $16.0 million in Q1 2026.
• Historically, Assets Average has averaged $44.0 million across 5 years, with a median of $42.1 million in 2024.
• Across the five-year window, Assets Average grew 3.19% in 2025 and sank 55.96% in 2026, its largest moves.
• Year by year, Assets Average stood at $56.6 million in 2022, then fell by 20.85% to $44.8 million in 2023, then slipped by 19.46% to $36.1 million in 2024, then retreated by 21.5% to $28.3 million in 2025, then sank by 43.52% to $16.0 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $16.0 million in Q1 2026, $28.3 million in Q4 2025, and $36.7 million in Q3 2025.